Crescita Therapeutics Inc. (TSE:CTX – Get Rating) Director Anthony Edward Dobranowski purchased 15,638 shares of Crescita Therapeutics stock in a transaction that occurred on Tuesday, August 16th. The stock was bought at an average cost of C$0.69 per share, with a total value of C$10,749.56. Following the completion of the transaction, the director now owns 100,000 shares of the company's stock, valued at C$68,740.
Crescita Therapeutics Price Performance
Shares of CTX opened at C$0.68 on Tuesday. Crescita Therapeutics Inc. has a 1-year low of C$0.55 and a 1-year high of C$0.83. The stock has a market cap of C$14.06 million and a PE ratio of -12.36. The company has a debt-to-equity ratio of 8.58, a current ratio of 3.10 and a quick ratio of 2.23. The firm has a fifty day moving average price of C$0.65 and a 200 day moving average price of C$0.68.
Get Crescita Therapeutics alerts:Crescita Therapeutics Company Profile
(Get Rating)
Crescita Therapeutics Inc, a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp.See Also
- MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
- Should You Buy These Copper Stocks Ahead Of Monster Demand?
- Three Industrial Stocks That Can Weather a Stormy Recession
- Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
- Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names
Receive News & Ratings for Crescita Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescita Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.